E-Slides

Access selected presentation slides from Heart Failure 2011

Thank you to all the attendees for making this year's congress a success and especially those who accepted to share their presentations here.

Date	Presentation	Speaker
21 May 2011	What is HFPEF and how to diagnose it.	Walter Paulus
21 May 2011	HFPEF and clinical outcomes: mortality, morbidity, symptoms and QoL.	John McMurray
21 May 2011	Treatment of HFPEF: evidence (or lack of it) and clinical approach.	Adriaan Voors
21 May 2011	HFPEF in the future: new diagnostic techniques and treatments in the pipeline.	Scott Solomon
22 May 2011	What is new in the guidelines?	John Camm
22 May 2011	Atrial fibrillation in heart failure: how big is the problem?	Frieder Braunschweig
22 May 2011	Ablation therapy in heart failure.	Zbigniew Kalarus
22 May 2011	ESC guidelines on heart failure.	Kenneth Dickstein
22 May 2011	Pathophysiology of thrombosis in heart failure.	Barry Massie
22 May 2011	Review of existing anticoagulation trials in heart failure.	John Cleland
22 May 2011	What will the WARCEF trial tell us about heart failure?	Stefan Anker
22 May 2011	What does exercise training do in heart failure?	Andrew Coats
22 May 2011	Results from randomized clinical trials.	Christopher O'Connor
22 May 2011	How to exercise?	Asa Cider
22 May 2011	Cardiac contractility modulation.	Martin Borggrefe
22 May 2011	Artificial heart.	Emma Jane Birks
22 May 2011	Mitral clip.	Magnus Settergren
22 May 2011	Ultrafiltration.	Alexandre Mebazaa
22 May 2011	Heart failure in the elderly - Is it only heart failure?	Burkert Mathias Pieske
22 May 2011	Atrial fibrillation in heart failure, importance of age.	Lars Kober
22 May 2011	Treatment-guidelines and one step beyond.	Hans Peter Brunner-La Rocca
22 May 2011	End-of-life decisions in elderly heart failure patients.	Lynne Warner Stevenson
22 May 2011	Is heart rate a treatment target?	Michael Bohm
22 May 2011	Do all symptomatics patients need 5 drugs or more?	Theresa McDonagh
22 May 2011	How should SHIfT and Emphasis influence guideline recommendations?	Kenneth Dickstein
22 May 2011	What are the implications for future trials in heart failure?	Henry Krum
22 May 2011	Link between chronic obstrutctive pulmonary disease and chronic heart failure.	Nathaniel Mark Hawkins
22 May 2011	Difficulty and challenge to diagnose chronic heart failure in chronic obstrutctive pulmonary disease.	Frans Hendrik Rutten
22 May 2011	How to optimise therapy for both: drugs to be preferred and avoided.	John T Parissis
22 May 2011	Health economy models - Too simplified.	Martin Cowie
22 May 2011	Are soft endpoints feasible?	Inger Ekman
22 May 2011	Qol what instruments to use: generic or disease specific?	Jillian Riley
22 May 2011	Too many questionnaires, how can we simplify?	Bradi Granger
22 May 2011	Assessing cardiovascular function in the elderly: the cardiopulmonary exercise test.	Lee Ingle
22 May 2011	Assessing cardiovascular function in the elderly: composite scores - Better than VO2 alone.	Lars Lund
22 May 2011	VADs in the elderly: too late?	Martin Strueber
22 May 2011	Care of the elderly with devices.	Bradi Granger
22 May 2011	Caring for cachectic heart failure patients - What can be done in 2011?	Mitja Lainscak
22 May 2011	Weight gain or muscle gain - Exercise programmes for heart failure patients.	Massimo Francesco Piepoli
22 May 2011	How to feed malnourished heart in heart failure.	Mihai Gheorghiade
22 May 2011	State-of-the-art: metabolic remodelling in heart failure.	Heinrich Taegtmeyer
22 May 2011	Immunoadsorption therapy in inflammatory heart disease.	Stephan Felix
22 May 2011	Is pulmonary hypertension important in heart failure?	Gerhard Wikstrom
22 May 2011	Pulmonary hypertension in heart failure.	Peter John Eriksson
22 May 2011	Assessing pulmonary circulation in clinical practice: are we focusing on the problem?	Odd Bech-Hanssen
22 May 2011	Treating the pulmonary circulation: why, when and how.	Marco Guazzi
23 May 2011	New natriuretic peptides.	Frank Ruschitzka
23 May 2011	Guanylate cyclase activators.	Mihai Gheorghiade
23 May 2011	Cardiac myosin activators.	John McMurray
23 May 2011	Calcium modulators.	Barry Massie
23 May 2011	Relaxin.	Adriaan Voors
23 May 2011	Cause of impaired erythropoiesis.	Adriaan Voors
23 May 2011	Which therapeutic role for Erythropoetin stimulating agents (ESA).	John R Teerlink
23 May 2011	Iron, combination therapies and new drugs on horizon.	Piotr Ponikowski
23 May 2011	Interaction with the renin-angiotensin system.	John McMurray
23 May 2011	Heart rate modulation.	Karl Swedberg
23 May 2011	Palliative care in heart failure - An overview.	Tiny Jaarsma
23 May 2011	Palliative care in patients with heart failure and cancer.	Mary Ryder
23 May 2011	Ethics in palliative care of patients in end-stage heart failure.	James Murray Beattie
23 May 2011	The impact of ICD shocks on morbidity and mortality.	John Camm
23 May 2011	How to avoid inappropriate shocks in heart failure patients.	Frank Ruschitzka
23 May 2011	Importance of psychosocial support for the ICD patient.	Selina Kikkenborg Berg
23 May 2011	Information to the potential ICD patient: how to be accurate.	Barbara Riegel
23 May 2011	Why do we need implantable monitoring solutions for the heart failure patient?	Lynne Warner Stevenson
23 May 2011	Remote heart failure monitoring in CRT and ICD patients in daily practice.	Frieder Braunschweig
23 May 2011	Implantable hemodynamic sensors.	Philip Adamson
23 May 2011	How to integrate monitoring into routine clinical work-flow.	Paul Hauptman
23 May 2011	The TIM-HF experience.	Friedrich Koehler
23 May 2011	Decision making from a distance – A case for biomarkers?!	Alan Maisel
23 May 2011	Overview and meta-analysis update.	John Cleland
23 May 2011	HDAC inhibitors.	Leon De Windt
23 May 2011	Myofilament-targeted agents.	Zoltan Papp
23 May 2011	Cam K antagonists.	Lars Siegfried Maier
23 May 2011	Iron and Epo - Treating anemia in heart failure.	Iain Macdougall
23 May 2011	Adenosine antagonists and the cardiorenal syndrome.	Carlo Gaillard
23 May 2011	Next generation beta-blocking by I-1 inhibition.	Ali El-Armouche
23 May 2011	PI3K inhibition to prevent maladaptive hypertrophy.	Emilio Hirsch
23 May 2011	Preexisting cardiovascular disease aggravated by pregnancy.	Vera Regitz-Zagrosek
23 May 2011	Managing heart failure in pregnancy and peripartum.	Karen Sliwa-Hahnle
23 May 2011	From myocardial infarction to heart failure – How do we prevent this?	John Kjekshus
23 May 2011	Perspectives of pharmacological therapy.	Jorge P Ribeiro
23 May 2011	Optimal candidate for coronary intervention.	Mark Petrie
24 May 2011	Markers of renal function.	Adriaan Voors
24 May 2011	Oxidative stress and inflammatory markers in heart failure.	Dimitris Tousoulis
24 May 2011	Copeptin in heart failure.	Christian Mueller
24 May 2011	Fibrosis and metalloproteinase.	Javier Diez Martinez
24 May 2011	Biomarkers as treatment targets.	Alan Maisel
24 May 2011	The dyspneic patient in the emergency department - Which biomarkers should we use and how?	Alan Maisel
24 May 2011	How to use new sensitive troponins in the era of the complex patient.	Christian Mueller
24 May 2011	Using biomarkers in the cardiorenal syndrome.	Claudio Ronco
24 May 2011	Using biomarkers to guide therapy.	Hans Peter Brunner-La Rocca
24 May 2011	Person-centred care - What is it?	Inger Ekman
24 May 2011	How to define the target population?	Marco Metra
24 May 2011	What is a clinically meaningful benefit? Symptoms vs. outcome.	Mihai Gheorghiade
24 May 2011	Mortality: an efficacy or a safety endoint?	Christopher O'Connor
24 May 2011	Potential future targets.	Alexandre Mebazaa
24 May 2011	Novel pathophysiological concepts for the development and impact of sleep apnea in chronic heart failure.	Olaf Oldenburg
24 May 2011	When heart, lung and brain are desynchronized - Should we be more focused on sleep apnea in chronic heart failure?	Martin Cowie
24 May 2011	How to assess symptoms in sleep apnea.	Anders Brostrom
24 May 2011	Future possibilities in treatment of sleep apnea.	Yuksel Peker
24 May 2011	Human spermatogonial cells.	Kaomei Guan
24 May 2011	Direct reprogramming of fibroblasts into cardiomyocytes.	Gerd Hasenfuss